Xia Cao1, Jiansong Zhou2, Zhiheng Chen1. 1. 1 Health Management Center, the Third Xiangya Hospital, Central South University , Changsha, Hunan Province, China . 2. 2 Mental Health Institute, the Second Xiangya Hospital, Central South University , Changsha, Hunan Province, China .
Abstract
AIMS: The aim of the present study was to re-establish a set of normative data for serum thymidine kinase 1 (STK1) for the Chinese population. METHODS: The study included 14,960 Chinese subjects (9586 males and 5374 females) from 20 to 79 years old. Subjects suffering from diseases that could affect STK1 levels were excluded. STK1 was measured by a sensitive chemiluminescence dot blot assay. The reference intervals were calculated using the LMS method. RESULTS: Peak thymidine kinase 1 (TK1) serum levels were observed at 20 years of age for both genders. After the age of 20 years, serum TK1 levels decreased slowly from 0.51 to 0.36 pM, reaching a plateau to a mean of 0.35 pM in late adulthood. The mean pretreatment STK1 Z-scores in patients with solid malignant tumors obtained from related studies for cancers were 0.01 ± 0.99 (males, -0.07 ± 0.97; females, 0.09 ± 1.02). CONCLUSIONS: The present study established age- and gender-specific normative STK1 data for the Chinese population and showed the utility of these references for screening patients with solid malignant tumors.
AIMS: The aim of the present study was to re-establish a set of normative data for serum thymidine kinase 1 (STK1) for the Chinese population. METHODS: The study included 14,960 Chinese subjects (9586 males and 5374 females) from 20 to 79 years old. Subjects suffering from diseases that could affect STK1 levels were excluded. STK1 was measured by a sensitive chemiluminescence dot blot assay. The reference intervals were calculated using the LMS method. RESULTS: Peak thymidine kinase 1 (TK1) serum levels were observed at 20 years of age for both genders. After the age of 20 years, serum TK1 levels decreased slowly from 0.51 to 0.36 pM, reaching a plateau to a mean of 0.35 pM in late adulthood. The mean pretreatment STK1 Z-scores in patients with solid malignant tumors obtained from related studies for cancers were 0.01 ± 0.99 (males, -0.07 ± 0.97; females, 0.09 ± 1.02). CONCLUSIONS: The present study established age- and gender-specific normative STK1 data for the Chinese population and showed the utility of these references for screening patients with solid malignant tumors.